Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGS-004 Immunotherapy in HIV-Infected Individuals
NCT02042248Phase 1Completed
- Start
- Mar 2014
- Primary completion
- May 2016
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, RNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of rocapuldencel-T in human immunodeficiency virus infection (HIV) (2 arms). Primary endpoint: CD8 T cell responses at 32 weeks. Started Mar 2014; status: completed.
02
Drugs
rocapuldencel-T
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02042248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02042248.